However, available data suggest that elucidating the role of galectin-3 in EBI would provide new insight into the mechanisms of EBI, and a novel therapeutic approach for EBI or neuroinflammation to prevent delayed cerebral infarction and to improve outcomes after SAH. Here, LGALS3 is linked to cerebral infarction.